

Trifluridine/Tipiracil (TAS-102) TAGS

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Trifluridine/Tipiracil (TAS-102) TAGS

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival




Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers
 Therapeutic Indication: Metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, in patients who have been previously treated with ≥ 2 prior systemic treatment regimens for advanced disease
 Experimental Arm: Trifluridine/Tipiracil (TAS-102)
 Control Arm: Placebo



